JBC Anatrace, Inc.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M508987200 on October 4, 2005

J. Biol. Chem., Vol. 280, Issue 52, 42601-42611, December 30, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow An addition or correction has been published
Right arrow All Versions of this Article:
280/52/42601    most recent
M508987200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Banerjee, Y.
Right arrow Articles by Kini, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Banerjee, Y.
Right arrow Articles by Kini, R. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Hemextin AB Complex, a Unique Anticoagulant Protein Complex from Hemachatus haemachatus (African Ringhals Cobra) Venom That Inhibits Clot Initiation and Factor VIIa Activity*

Yajnavalka Banerjee{ddagger}1, Jun Mizuguchi§, Sadaaki Iwanaga§, and R. Manjunatha Kini{ddagger}2

From the {ddagger}Protein Science Laboratory, Department of Biological Sciences, Faculty of Science, National University of Singapore Singapore 117543, the §Blood Products Research Department, The Chemo-Sero-Therapeutic Research Institute, Kumamoto 869-1298, Japan, and the Department of Biochemistry, Virginia Commonwealth University Medical Center, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298

Received for publication, August 15, 2005 , and in revised form, September 28, 2005.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
During injury or trauma, blood coagulation is initiated by the interaction of factor VIIa (FVIIa) in the blood with freshly exposed tissue factor (TF) to form the TF·FVIIa complex. However, unwanted clot formation can lead to death and debilitation due to vascular occlusion, and hence, anticoagulants are important for the treatment of thromboembolic disorders. Here, we report the isolation and characterization of two synergistically acting anticoagulant proteins, hemextins A and B, from the venom of Hemachatus haemachatus (African Ringhals cobra). N-terminal sequences and CD spectra of the native proteins indicate that these proteins belong to the three-finger toxin family. Hemextin A (but not hemextin B) exhibits mild anticoagulant activity. However, hemextin B forms a complex (hemextin AB complex) with hemextin A and synergistically enhances its anticoagulant potency. Prothrombin time assay showed that these two proteins form a 1:1 complex. Complex formation was supported by size-exclusion chromatography. Using a "dissection approach," we determined that hemextin A and the hemextin AB complex prolong clotting by inhibiting TF·FVIIa activity. The site of anticoagulant effects was supported by their inhibitory effect on the reconstituted TF·FVIIa complex. Furthermore, we demonstrated their specificity of inhibition by studying their effects on 12 serine proteases; the hemextin AB complex potently inhibited the amidolytic activity of FVIIa in the presence and absence of soluble TF. Kinetic studies showed that the hemextin AB complex is a noncompetitive inhibitor of soluble TF·FVIIa amidolytic activity, with a Ki of 50 nM. Isothermal titration calorimetric studies showed that the hemextin AB complex binds directly to FVIIa with a binding constant of 1.62 x 105 M–1. The hemextin AB complex is the first reported natural inhibitor of FVIIa that does not require a scaffold to mediate its inhibitory activity. Molecular interactions of the hemextin AB complex with FVIIa/TF·FVIIa will provide a new paradigm in the search for anticoagulants that inhibit the initiation of blood coagulation.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Blood coagulation is an innate response to vascular injury that results from a series of amplified reactions in which zymogens of serine proteases circulating in the plasma are sequentially activated by limited proteolysis, leading to the formation of blood clot, thereby preventing the loss of blood (1–3). It is initiated through the extrinsic pathway (4). Membrane-bound tissue factor (TF),3 exposed during vascular injury, interacts with factor VIIa (FVIIa), which preexists in the plasma (at 1–2% of total factor VII) (5, 6), and forms the extrinsic tenase complex. This complex activates FX to FXa. In association with its cofactor FVa, FXa performs a proteolytic cleavage of prothrombin to thrombin. Thrombin cleaves fibrinogen to fibrin, promoting the formation of a fibrin clot, and activates platelets for inclusion in the clot. The TF·FVIIa complex can also activate FIX to FIXa, thus helping in the propagation of the coagulation cascade through the intrinsic pathway. The coagulation cascade is under tight regulation. Any imbalance in its regulation could lead to either unclottable blood, resulting in excessive bleeding during injuries, or unwanted clot formation, resulting in death and debilitation due to vascular occlusion with the consequence of myocardial infarction, stroke, pulmonary embolism, or venous thrombosis (3). Therefore, there is an urgent need for the prophylaxis and treatment of thromboembolic disorders.

Anticoagulants are pivotal for the prevention and treatment of thromboembolic disorders, and ~0.7% of the western population receives oral anticoagulant treatment (7). Coumarins and heparin are the most well known clinically used anticoagulants. Coumarins inhibit the activity of all vitamin K-dependent proteins, including procoagulants (thrombin, FXa, FIXa, and FVIIa) and anticoagulants (activated protein C and protein S), whereas heparin mediates its anticoagulant activity by enhancing the inhibition of thrombin and FXa by antithrombin III (8, 9). The nonspecific mode of action of these anticoagulants accounts for their therapeutic limitations in maintaining a balance between thrombosis and hemostasis (10). These limitations have provided the impetus for the development of new anticoagulants that target specific coagulation enzymes or a particular step in the clotting process (11, 12). Because of its relatively low concentrations in blood (10 nM) and its pivotal role in the initiation of the coagulation cascade (13), FVII/FVIIa is an attractive drug target for the development of novel and specific anticoagulant agents.

Proteins/toxins from snake venoms have inspired the design and development of a number of therapeutic agents or lead molecules, particularly for cardiovascular diseases (14). For example, a family of inhibitors of angiotensin-converting enzyme was developed based on bradykinin-potentiating peptides from South American snake venoms (15). Inhibitors of platelet aggregation, such as eptifibatide and tirofiban, were designed based on disintegrins, a large family of platelet aggregation inhibitors found in viperid and crotalid snake venoms (16–21). Ancrod (extracted from the venom of the Malayan pit viper) reduces blood fibrinogen levels and has been successfully tested in a variety of ischemic conditions, including stroke (22). To search for new lead molecules, we and others have been focusing on isolating and characterizing pharmacologically active proteins from snake venoms that affect blood coagulation and platelet aggregation. In this study, we report the purification and characterization of a three-finger toxin that mediates anticoagulant activity from the venom of the elapid snake Hemachatus haemachatus (African Ringhals cobra). Although it has mild anticoagulant activity, its synergistic interaction with the second three-finger toxin enhances its anticoagulant potency. The anticoagulant protein and its complex specifically inhibit the activation of FX by the TF·FVIIa complex by noncompetitively inhibiting the enzymatic activity of FVIIa. This is the first report of a naturally occurring FVIIa inhibitor that does not require a scaffold to mediate its inhibitory activity.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Materials
Lyophilized H. haemachatus venom was obtained from African Reptiles and Venoms (Gauteng, South Africa). Thromboplastin with calcium (for prothrombin time assays), Russell's viper venom (for Stypven time assays), thrombin reagent (for thrombin time assays), benzamidine hydrochloride, and 4-vinylpyridine were purchased from Sigma. beta-Mercaptoethanol was purchased from Nacalai Tesque (Kyoto, Japan). The chromogenic substrates H-D-Ile-Pro-Arg-p-nitroanilide (pNA) dihydrochloride (2HCl) (S-2288), <Glu-Pro-Arg-pNA·HCl (S-2366), H-D-Phe-pipecolyl-Arg-pNA·2HCl (S-2238), H-D-Pro-Phe-Arg-pNA·2HCl (S-2302), Z-D-Arg-Gly-Arg-pNA·2HCl (S-2765), <Glu-Gly-Arg-pNA·HCl (S-2444), benzoyl-Ile-Glu(Glu-{gamma}-methoxy)-Gly-Arg-pNA·HCl (S-2222), H-D-Val-Leu-Lys-pNA·2HCl (S-2251), H-D-Val-Leu-Arg-pNA·2HCl (S-2266), and methoxysuccinyl-Arg-Pro-Tyr-pNA·HCl (S-2586) were from Chromogenix AB (Stockholm, Sweden). Spectrozyme® FIXa (H-D-Leu-phenylalanyl-Gly-Arg-pNA·2-AcOH) was obtained from American Diagnostica Inc. (Stamford, CT). All substrates were reconstituted in deionized water prior to use. Recombinant human TF (Innovin) was purchased from Dade Behring (M-arburg, Germany). Human plasma was donated by healthy volunteers. All other chemicals and reagents used were of the highest purity available.

Proteins
Human plasma-derived FVIIa, FX, and FXa were a gift from the Factor VII Group (Kazuhiko Tomokiyo, Yasushi Nakatomi, Teruhisa Nakashima, and Soutatou Gokudan) of KAKETSUKEN and were purified as described (23, 24). Recombinant human soluble TF (sTF; residues 1–218) was a gift from Dr. Toshiyuki Miyata (National Cardiovascular Center, Suita, Japan), and it was prepared as described (25). Human plasma-derived thrombin, activated protein C, and FIXa were gifts from Hiroshi Kaetsu, Shinji Nakahira, and Takayoshi Hamamoto (KAKETSUKEN), respectively, and prepared as described (23, 26, 27). Three cardiotoxins (CM-14, CM-17, and CM-18 from Naja naja atra) were obtained from Dr. Mitsuhiro Ohta (Kobe Pharmaceutical University). Plasma kallikrein and plasmin were purchased from Enzyme Research Laboratories (South Bend, IN). FXIa and FXIIa were purchased from Haemtech (Essex Junction, VT). Tissue plasminogen activator and urokinase-type plasminogen activator were purchased from American Diagnostica Inc. {alpha}-Chymotrypsin and trypsin were obtained from Worthington.

Purification of Anticoagulant Protein
H. haemachatus crude venom (100 mg in 1 ml of distilled water) was applied to a Superdex 30 gel-filtration column (1.6 x 60 cm) equilibrated with 50 mM Tris-HCl buffer (pH 7.4) and eluted with the same buffer using an {Delta}KTA purifier system (Amersham Biosciences AB, Uppsala, Sweden). Individual fractions were assayed for anticoagulant activity using prothrombin time (see below). Fractions with potent anticoagulant activity were pooled and subfractionated on a cation-exchange column using the same chromatography system. The anticoagulant fraction was pooled and loaded onto a UNO S6 column (6-ml column volume; Bio-Rad) equilibrated with 50 mM Tris-HCl buffer (pH 7.5). Bound proteins were eluted with a linear gradient of 1 M NaCl in the same buffer. Fractions collected were assayed for anticoagulant activity. The anticoagulant peaks obtained from cation-exchange chromatography were applied to a Jupiter C18 column (1 x 25 cm) equilibrated with 0.1% trifluoroacetic acid. The bound proteins were eluted using a linear gradient of 80% acetonitrile in 0.1% trifluoroacetic acid. Individual peaks were collected, lyophilized, examined for anticoagulant activity, and subsequently rechromatographed on a narrow bore PepMap column using a Chromeleon microliquid chromatography system (LC Packings, San Francisco, CA).

Electrospray Ionization Mass Spectrometry
The homogeneity and mass of the anticoagulant proteins were determined by electrospray ionization mass spectrometry using a PerkinElmer Life Sciences API-300 liquid chromatography/tandem mass spectrometry system. Typically, reverse-phase HPLC fractions were directly used for analysis. Ion spray, orifice, and ring voltages were set at 4600, 50, and 350 V, respectively. Nitrogen was used as a nebulizer and curtain gas. A Shimadzu LC-10AD pump was used for solvent delivery (40% acetonitrile in 0.1% trifluoroacetic acid) at a flow rate of 50 µl/min. BioMultiview software (PerkinElmer Life Sciences) was used to analyze and deconvolute raw mass spectra.

Reduction and Pyridylethylation
Purified proteins were reduced and pyridylethylated using procedures described previously (28). Briefly, proteins (0.5 mg) were dissolved in 500 µl of denaturant buffer (6 M guanidine hydrochloride, 0.25 M Tris-HCl, and 1 mM EDTA (pH 8.5)). After the addition of 10 µl of beta-mercaptoethanol, the mixture was incubated under vacuum for 2 h at 37 °C. 4-Vinylpyridine (50 µl) was added to the mixture and kept at room temperature for 2 h. Pyridylethylated proteins were purified on an analytical Jupiter C18 column (4.6 x 250 mm) using a gradient of acetonitrile in 0.1% (v/v) trifluoroacetic acid at a flow rate of 0.5 ml/min.

N-terminal Sequencing
N-terminal sequencing of the native and S-pyridylethylated proteins was performed by automated Edman degradation using a PerkinElmer Life Sciences Model 494 pulsed liquid-phase sequencer (Procise) with an on-line Model 785A phenylthiohydantoin-derivative analyzer.

CD Spectroscopy
Far-UV CD spectra (260–190 nm) were recorded using a Jasco J-810 spectropolarimeter. All measurements were carried out at room temperature using 0.1-cm path length stoppered cuvettes. The instrument optics was flushed with 30 liters of nitrogen gas/min. The spectra were recorded using a scan speed of 50 nm/min, a resolution of 0.2 nm, and a bandwidth of 2 nm. A total of four scans were recorded and averaged for each spectrum, and the base line was subtracted. The CD spectra of the anticoagulant proteins and their S-pyridylethylated forms were recorded in 50 mM Tris-HCl buffer (pH 7.4).

Reconstitution of the Anticoagulant Complex
Preliminary studies indicated that the active anticoagulant protein interacted with another venom protein, forming a synergistic complex. We reconstituted the complex for various in vitro experiments immediately prior to the experiments by incubating equimolar concentrations of the two proteins (unless mentioned otherwise) at 37 °C for 5 min in 50 mM Tris-buffer (pH 7.4).

Anticoagulant Activity
The anticoagulant activities of H. haemachatus venom and its fractions were determined by four coagulation tests using a BBL Fibrometer.

Recalcification Time—The recalcification times were determined according to the method of Langdell et al. (29). 50 mM Tris-HCl buffer (pH 7.4; 100 µl), plasma (100 µl), and various concentrations of venom or its fraction (50 µl) were preincubated for 2 min at 37 °C. Clotting was initiated by the addition of 50 µl of 50 mM CaCl2.

Prothrombin Time—The prothrombin times were measured according to the method of Quick (30). 100 µl of 50 mM Tris-HCl buffer (pH 7.4), 100 µl of plasma, and 50 µl of venom or its fractions were preincubated for 2 min at 37 °C. Clotting was initiated by the addition of 150 µl of thromboplastin with calcium reagent.

Stypven Time—The Stypven times were measured according to the method of Hougie (31). Plasma (100 µl), 50 mM Tris-HCl buffer (pH 7.4; 100 µl), Russell's viper venom (0.01 µg in 100 µl), and individual proteins or the reconstituted complex (50 µl) were preincubated for 2 min at 37 °C. Clotting was initiated by the addition of 50 µl of 50 mM CaCl2.

Thrombin Time—The thrombin times were determined according to the method of Jim (32). Individual proteins or the reconstituted complex was incubated with 100 µl of plasma and 100 µl of 50 mM Tris-HCl buffer (pH 7.4) for 2 min at 37 °C in a total volume of 250 µl. Clotting was initiated by the addition of standard thrombin reagent (0.01 NIH unit in 50 µl).

Complex Formation Studies with Size-exclusion Chromatography
The formation of a complex between anticoagulant proteins was examined by gel-filtration chromatography on a Superdex 30 gel-filtration column (1.6 x 60 cm) using an {Delta}KTA purifier. The column was equilibrated with 50 mM Tris-HCl buffer (pH 7.4) at a flow rate of 1 ml/min. Individual proteins and an equimolar mixture of anticoagulant proteins (native or pyridylethylated) were incubated for 30 min at 37 °C and then loaded onto the column and eluted in the same buffer. Elution was followed at 280 nm.

Reconstitution of the Extrinsic Tenase Complex
The TF·FVIIa complex was reconstituted by incubating 10 pM FVIIa with 70 pM recombinant human TF (Innovin) in Buffer A (20 mM HEPES, 150 mM NaCl, 10 mM CaCl2, and 1% bovine serum albumin (pH 7.4)) for 10 min at 37 °C. FX was added to the mixture to obtain a final concentration of 30 nM. The activation was stopped by the addition 50 µl of stop buffer (20 mM HEPES, 150 mM NaCl, 50 mM EDTA, and 1% bovine serum albumin (pH 7.4)) to 50-µl aliquots of the reaction mixture after 15 min of incubation. FXa formed was measured by the hydrolysis of 1 mM S-2222 in Buffer A in a microtiter plate reader at 405 nm. The inhibitory effect on extrinsic tenase activity was determined by adding the individual proteins or the anticoagulant complex 15 min prior to FX addition.

Serine Protease Specificity
The selectivity profile of anticoagulant proteins and their complex was examined against 12 serine proteases: procoagulant serine proteases (FIXa, FXa, FXIa, FXIIa, plasma kallikrein, and thrombin), anticoagulant serine protease activated protein C, fibrinolytic serine proteases (urokinase, tissue plasminogen activator, and plasmin), and classical serine proteases (trypsin and chymotrypsin). Various concentrations of the purified individual proteins or the reconstituted anticoagulant complex were preincubated with each of the enzymes for 5 min at 37 °C, followed by the addition of the appropriate chromogenic substrate.

In a total volume of 200 µl in the individual wells of the microtiter plate, the final concentrations were as follows: FVIIa (300 nM)/S-2288, sTF·FVIIa (30 nM)/S-2288, FXa (0.75 nM)/S-2765, {alpha}-thrombin (0.66 nM)/S-2238, plasmin (2 nM)/S-2251, FIXa (3 µM)/Spectrozyme® FIXa, FXIa (0.34 nM)/S-2366, FXIIa (0.4 nM)/S-2302, recombinant tissue plasminogen activator (80 nM)/S-2288, activated protein C (0.34 nM)/S-2366, urokinase/S-2444, plasma kallikrein (0.4 nM)/S-2302, trypsin (2.17 nM)/S-2222, and chymotrypsin (0.4 nM)/S-2586. The kinetic rate of substrate hydrolysis (mOD/min) was measured over 5 min.

Kinetics of Inhibition
All studies were performed in 50 mM Tris-HCl buffer (pH 7.4) containing 150 mM NaCl, 10 mM CaCl2, and 1% bovine serum albumin at 37 °C. The kinetics of hydrolysis of the chromogenic substrate S-2288 by sTF·FVIIa was measured prior to examining the inhibitory effects of the individual proteins and the reconstituted anticoagulant complex. Reactions were initiated by the addition of S-2288 (0–5 mM) to the individual wells of a 96-well plate containing FVIIa (30 nM) in complex with sTF (100 nM) in a final volume of 180 µl. Initial reaction velocities were measured as a linear increase in the absorbance at 405 nm over 5 min with a SpectraMax Plus® temperature-controlled microplate spectrophotometer (Molecular Devices Corp., Sunnyvale, CA).

The inhibitory potency of the anticoagulant complex was measured over a range of substrate concentrations. Reactions were initiated by the addition of S-2288 to premixed cofactor·enzyme and inhibitor in the wells of a microtiter plate. Reactions with sTF·FVIIa contained 0.025–0.1 µM inhibitor complex and 0–3 mM S-2288. The initial velocities were measured over 5 min under steady-state conditions and were fit by reiterative nonlinear regression to Equation 1, describing a classical noncompetitive inhibitor, to derive the Ki value.

Formula 1(Eq. 1)

Isothermal Titration Calorimetry (ITC)
The interaction of the reconstituted anticoagulant complex with FVIIa was monitored with a VP-ITC titration calorimetric system (MicroCal, LLC, Northampton, MA). The instrument was calibrated using the built-in electrical calibration check. FVIIa (10 µM) in 50 mM Tris-HCl buffer and 10 mM CaCl2 (pH 7.4) in the calorimetric cell was titrated with the reconstituted anticoagulant complex (0.4 mM) dissolved in the same buffer in a 250-µl injection syringe with continual stirring at 300 rpm at 37 °C. All protein solutions were filtered and degassed prior to titration. The first injections presented defects in the base line, and these data were not included in the fitting process. The calorimetric data were processed and fitted to the single set of identical sites model using MicroCal Origin (Version 7.0) data analysis software supplied with the instrument. The total heat content (Q) of the solution (determined relative to zero for the unliganded species) contained in the active cell volume (V0) was calculated according to Equation 2,

Formula 2(Eq. 2)
where K is the binding affinity constant; n is the number of sites; {Delta}H is the enthalpy of ligand binding; and Mt and Xt are the bulk concentrations of macromolecule and ligand, respectively, for the binding X + M {leftrightarrow} XM. The change in heat ({Delta}H) measured between the completions of two consecutive injections is corrected for dilution of the protein and ligand in the cell according to standard Marquardt methods. The free energy change ({Delta}G) during the interaction was calculated using the relationship {Delta}G = {Delta}H–T{Delta}S = –RT ln Ka, where T is the absolute temperature and R is the universal gas constant.


Figure 1
View larger version (11K):
[in this window]
[in a new window]
  		FIGURE 1.
Anticoagulant activity of the crude venom. Shown are the effects of the crude venom on recalcification time (A) and prothrombin time (B). Note that the venom exhibited potent anticoagulant activity in both assays. Each data point represents the mean ± S.D.

 

   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Purification of the Anticoagulant Protein—Crude venom of H. haemachatus exhibited potent anticoagulant activity in both recalcification and prothrombin time assays (Fig. 1, A and B). To purify the anticoagulant protein, the crude venom was size-fractionated by gel-filtration chromatography (Fig. 2A). Fractions corresponding to peaks 2 and 3 contained anticoagulant proteins as determined by prothrombin time assays. Peak 2 corresponded to proteins mostly containing phospholipase A2 that have been characterized previously (33). However, this peak had milder anticoagulant activity compared with peak 3 (Fig. 2A, inset), so we focused on isolating the anticoagulant protein from peak 3, which was fractionated further by cation-exchange chromatography on a UNO S6 column (Fig. 2B). Only peak A (labeled Hemextin A) exhibited mild anticoagulant activity. During our preliminary studies, we found that the anticoagulant activity of peak A was potentiated by peak B (labeled Hemextin B; see below). Because this anticoagulant complex specifically inhibited the extrinsic tenase complex (described below), we named it the hemextin AB complex (Hemachatus extrinsic tenase inhibitor) and the individual proteins hemextins A and B, respectively. Fractions corresponding to both hemextins A and B were pooled separately and purified by reverse-phase HPLC (Fig. 2, C and D) and capillary liquid chromatography (Fig. 2, E and F). The homogeneity and mass of the individual proteins were determined by electrospray ionization mass spectrometry. The mass spectra of hemextins A and B showed three peaks with mass/charge ratios ranging from 3 to 6 charges (data not shown) and their calculated molecular masses as 6835.00 ± 0.52 and 6792.56 ± 0.32 Da, respectively (Fig. 2, G and H).


Figure 2
View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 2.
Purification of hemextins A and B. A, size-exclusion chromatography of H. haemachatus crude venom using a Superdex 30 column. Inset, anticoagulant activity of peaks 2 and 3. B, cation-exchange chromatography of peak 3 using a UNO S6 column. C and D, reverse-phase HPLC profiles of fractions containing hemextins A and B, respectively, using a Jupiter C18 semipreparative column. E and F, capillary liquid chromatography profiles of hemextins A and B, respectively. The homogeneity and mass of hemextins A and B were determined by electrospray ionization mass spectrometry. G and H, reconstructed mass spectra of hemextins A and B, respectively. CPS, counts/s; amu, atomic mass units.

 


Figure 3
View larger version (43K):
[in this window]
[in a new window]
  		FIGURE 3.
N-terminal sequences of hemextins A and B. A, the first 25 N-terminal residues of hemextins A and B were determined by Edman degradation. Conserved cysteine residues in the three-finger toxin family are indicated. B, shown are the CD spectra of native and S-pyridylethylated hemextins A and B.

 
N-terminal Sequence Determination—We determined the sequence of the first 25 amino acid residues of hemextins A and B by Edman degradation (Fig. 3A). The locations of the cysteine residues in the proteins were confirmed by sequencing the pyridylethylated proteins. Both proteins show similarity to cardiotoxins, postsynaptic neurotoxins, fasciculin, and other members of the three-finger toxin family (Fig. 3A), but not to serine protease inhibitors isolated from snake venoms (34, 35). Thus, hemextins A and B belong to three-finger toxin family.

CD Spectroscopy—Both hemextins A and B exhibited negative minima at 215 nm and positive maxima at 194 nm. Thus, similar to other three-finger toxins, both hemextins A and B exhibited a predominantly beta-sheet structure (Fig. 3B). However, the S-pyridylethylated forms of hemextins A and B displayed negative minima at 195 nm, i.e. a predominantly random-coil structure (Fig. 3B). Thus, reduction and pyridylethylation result in the loss of folding and three-dimensional structure in hemextins A and B.

Anticoagulant Activity of Hemextins—The anticoagulant activity of hemextins A and B was determined by the prothrombin time assay (Fig. 4A). Hemextin A prolonged the clotting time and exhibited mild anticoagulant activity, whereas hemextin B did not show any significant effect on the clotting time even at higher concentrations. Interestingly, an equimolar mixture of hemextins A and B exhibited more potent anticoagulant activity, indicating synergism between these proteins (Fig. 4A). Such an increase in the anticoagulant effect could be due either to the inhibition of two separate steps in the coagulation cascade or to the formation of a complex between them. Because hemextin B by itself has no significant effect on prothrombin time, it does not inhibit a separate step; instead, it is likely that hemextins A and B form a complex. S-Pyridylethylated hemextins did not exhibit any anticoagulant activity. An equimolar mixture of S-pyridylethylated hemextins A and B also failed to display any anticoagulant effect (Fig. 4A, inset). Thus, proper folding is important for the interaction between hemextins A and B and their anticoagulant activity.


Figure 4
View larger version (21K):
[in this window]
[in a new window]
  		FIGURE 4.
Effects of hemextins A and B on prothrombin time. A, shown are the effects of hemextin A ({circ}), hemextin B ({square}), and the probable hemextin AB complex ({blacktriangleup}) on prothrombin time. Note that the anticoagulant potency of hemextin A increased in the presence of hemextin B. Each data point represents the mean ± S.D. Inset, comparison of the anticoagulant activities of the control (C), S-pyridylethylated hemextin A (S-HA), S-pyridylethylated hemextin B (S-HB), a mixture of S-pyridylethylated hemextins A and B (S-HAB), hemextin A (HA), hemextin B (HB), and the hemextin AB complex (HAB). B, complex formation between hemextins A and B is illustrated by their effect on prothrombin time.

 
Complex Formation between Hemextins A and B—To investigate the formation of a complex between the two proteins, we employed a titration experiment in the prothrombin time assay. In this experiment, the concentration of hemextin A was kept constant at 4.4 µM, and its anticoagulant activity was monitored with increasing hemextin B concentrations (Fig. 4B). The anticoagulant activity increased with increasing concentrations of hemextin B until the ratio reached 1:1. Further addition did not increase the anticoagulant effect. The results indicate that hemextins A and B form a 1:1 complex and that complex formation is crucial for potent anticoagulant activity.

Complex formation between hemextins A and B was further confirmed by gel-filtration chromatography. As shown in Fig. 5, the retention time of individual hemextins A and B was ~70 min. However, the reconstituted complex eluted as a major peak with a retention time of ~40 min and as a minor peak with a retention time of ~70 min. The appearance of the major peak with a reduced retention time corresponding to ~27 kDa is consistent with the formation of a tetrameric complex with two molecules each of hemextins A and B. We also reconstituted the hemextin AB complex with S-pyridylethylated forms of the native proteins. However, no change in the retention time of the mixture was observed compared with those of the individual S-pyridylethylated proteins (Fig. 5). These results indicate that proper folding is essential for the formation of the hemextin AB complex.


Figure 5
View larger version (13K):
[in this window]
[in a new window]
  		FIGURE 5.
Gel-filtration studies on the formation of the hemextin AB complex. Note that the elution time of the hemextin AB complex was reduced to ~40 min compared with that of the individual hemextins (~70 min). Also note that the mixture of S-pyridylethylated hemextins A and B was unable to form a complex.

 
It is important to note that hemextins A and B do not exist as a complex in the crude venom. Complex formation is probably hindered by the presence of high concentrations of citrate and other salts in the venom. The reconstituted hemextin AB complex could be easily separated into individual components on a cation-exchange column (data not shown).

Site of Anticoagulant Activity—As shown above, hemextin A and its complex with hemextin B prolonged prothrombin time (Fig. 4A). To identify the specific stage in the extrinsic coagulation pathway, we used a simple "dissection approach" (36, 37). We employed three commonly used clotting time assays, viz. prothrombin time, Stypven time, and thrombin time. This approach is based on the principle that initiating the cascade "upstream" from the inhibited step will result in elevated clotting times, whereas initiating the cascade "downstream" from the inhibited step will not affect clotting times. Thus, the anticoagulant action of the individual proteins and the complex can be localized to certain activation step(s) in the cascade (for details, see Refs. 32 and 33). Hemextin A exhibited mild anticoagulant activity by prolonging the clotting time in the prothrombin time assay, but did not prolong Stypven time and thrombin time (data not shown). As expected, hemextin B did not prolong clotting times in the prothrombin time, Stypven time, and thrombin time assays. The hemextin AB complex exhibited potent anticoagulant activity by prolonging the clotting time in the prothrombin time assay. However, the clotting times in the other two assays were not affected (data not shown). These results indicate that hemextin A and the hemextin AB complex affect only the extrinsic tenase complex, but not the prothrombinase complex or conversion of fibrinogen to fibrin clots.


Figure 6
View larger version (16K):
[in this window]
[in a new window]
  		FIGURE 6.
Inhibition of TF·FVIIa activity. A, shown is the hemextin A ({blacktriangleup}), hemextin B ({blacksquare}), and hemextin AB complex ({circ}) inhibitory potency on TF·FVIIa activity. B, the formation of the hemextin AB complex (•) between hemextin A ({blacksquare}) and hemextin B is illustrated by their effect on TF·FVIIa enzymatic activity. To determine the stoichiometry of complex formation, the concentration of hemextin A was kept low so that 100% TF·FVIIa activity was not inhibited upon complex formation.

 
To confirm the site of inhibition, we examined the effects of hemextins A and B and their complex on the reconstituted TF·FVIIa complex (Fig. 6A). Hemextin A exhibited mild inhibitory activity at higher concentrations. On the other hand, hemextin B did not mediate any inhibitory activity on the enzymatic action of the extrinsic tenase complex. However, the hemextin AB complex completely inhibited extrinsic tenase activity (Fig. 6A) with an IC50 (concentration of the inhibitor that inhibits 50% of the activity) of 200 nM. Neither the individual proteins nor the complex mediated any inhibitory effect on FXa amidolytic activity (described below). The effects of the individual hemextins and the hemextin AB complex on the intrinsic pathway were also assessed using recalcification time assays. No anticoagulant activity on the intrinsic pathway was observed (data not shown). Furthermore, the effects of other three-finger toxins, particularly cardiotoxins/cytotoxins, which are structurally similar to hemextins A and B, on TF·FVIIa proteolytic activity were also monitored. CM-14, CM-17, and CM-18 from N. naja atra did not inhibit FXa formation by the TF·FVIIa complex (data not shown). To determine the importance of hemextin AB complex formation for the inhibition of the TF·FVIIa complex, we performed a similar titration experiment. The inhibitory activity of hemextin A at 50 µM (the concentration at which the hemextin AB complex inhibited only ~70% of the TF·FVIIa activity) was examined in the presence of increasing concentrations of hemextin B. As shown in Fig. 6B, the inhibitory activity of hemextin A increased with increasing concentrations of hemextin B until the ratio reached 1:1. Further addition did not increase the inhibition. The results indicate that hemextins A and B form a 1:1 complex and that complex formation is crucial for potent anticoagulant activity. These observations further confirm the importance of complex formation between hemextins A and B.


Figure 7
View larger version (16K):
[in this window]
[in a new window]
  		FIGURE 7.
Effect of phospholipids on the inhibitory activity of hemextins A and B and the hemextin AB complex. Shown is the hemextin A (•), hemextin B ({blacktriangleup}), and hemextin AB complex ({blacksquare}) inhibitory potency on FVIIa (A) and sTF·FVIIa (B) amidolytic activity. Note that the absence of phospholipids did not affect the inhibitory potency of the protein(s) and the reconstituted complex.

 
To understand the effect of phospholipids, the inhibitory activity of hemextin A and the hemextin AB complex on FVIIa amidolytic activity was monitored in the presence or absence of sTF. In both the cases, we observed potent inhibitory activity in a dose-dependent manner (Fig. 7, A and B).

Specificity of Inhibition—To determine the specificity of inhibition, hemextins A and B and their complex were screened against 12 serine proteases. No inhibitory activity was observed against any of the serine proteases with the exception of FVIIa and plasma kallikrein. As with FVIIa, hemextin A and the hemextin AB complex inhibited plasma kallikrein in a dose-dependent manner (Fig. 8). Hemextin B did not inhibit the protease activity of kallikrein. However, the inhibitory potency for FVIIa (in the absence or presence of sTF) was at least 50 times higher than for plasma kallikrein.

Kinetics of Inhibition—To determine the mechanism of inhibition, we examined the kinetics of hemextin AB complex inhibition of the amidolytic activity of the sTF·FVIIa complex in the presence of S-2288. Kinetic studies revealed that hemextin inhibited sTF·FVIIa activity noncompetitively. Lineweaver-Burk plots showed that Km values remained unaltered, whereas Vmax values decreased with increasing concentrations of the inhibitor (Fig. 9A), a characteristic of a noncompetitive inhibitor. The Ki for inhibition was determined to be 50 nM (Fig. 9B). We also calculated the turnover number (Kcat; moles of substrate converted to product/mol/enzyme/min) at different concentrations of the inhibitor. As observed in the case of classical noncompetitive inhibitors, the Kcat decreased with increasing concentrations of the hemextin AB complex (data not shown). Because the amidolytic activity of FVIIa alone is very weak (38), we did not study the kinetics of the inhibition of FVIIa amidolytic activity by the hemextin AB complex.


Figure 8
View larger version (10K):
[in this window]
[in a new window]
  		FIGURE 8.
Inhibition of plasma kallikrein amidolytic activity. Shown is the hemextin A ({blacktriangleup}), hemextin B (•), and hemextin AB complex ({blacksquare}) inhibitory potency on plasma kallikrein amidolytic activity. Note that the IC50 for inhibition was ~10 µM.

 


Figure 9
View larger version (13K):
[in this window]
[in a new window]
  		FIGURE 9.
Nature of inhibition. A, double-reciprocal (Lineweaver-Burk) plots for the kinetic activity of sTF·FVIIa in the presence of 100 nM ({square}; 2Ki), 50 nM ({circ}; Ki), and 25 nM ({blacksquare}; 1/2Ki) reconstituted hemextin AB complex. Also shown is the kinetic activity of sTF·FVIIa in the absence of the hemextin AB complex (•). Note that the Vmax decreased with increasing inhibitor concentrations, whereas the Km remained unchanged, a classical phenomenon observed in noncompetitive inhibitors. B, corresponding secondary plot depicting the Ki for inhibition. mOD, milli-optical density.

 


Figure 10
View larger version (17K):
[in this window]
[in a new window]
  		FIGURE 10.
ITC studies on the formation of a complex between the hemextin AB complex and FVIIa. A, raw data in microcalories/s versus time showing heat release upon injections of 0.4 mM reconstituted hemextin AB complex into a 1.4-ml cell containing 10 µM FVIIa; B, integration of the raw data yielding the heat/mol versus molar ratio. The best values of the fitting parameters were 1.62 x 105 M–1 for K, –5.445 kcal·M–1 for {Delta}H, and –4.274 cal·M–1 for {Delta}S.

 
Binding of the Hemextin AB Complex to FVIIa—We studied the interaction between the hemextin AB complex and FVIIa by ITC. We monitored the thermodynamic changes associated with the binding of the hemextin AB complex to FVIIa (Fig. 10). The binding was exothermic, with {Delta}H=–5.445 kcal·M–1, {Delta}G=–4.121 kcal·M–1, and {Delta}S=–4.274 cal·M–1. The calculated K for the binding was 1.62 x 105 M–1.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Initiation of blood coagulation during injury or trauma is essential for the survival of the organism. However, the formation of unwanted clots has detrimental or debilitating effects and hence the need for anticoagulant therapies. The current anticoagulants used for treating these disorders are nonspecific and have a narrow therapeutic range, necessitating careful laboratory monitoring to achieve optimal efficacy and to minimize bleeding. This is further complicated by other factors such as dietary intake (39). Therefore, novel anticoagulant and antiplatelet agents are being sought. Because FVIIa is the key initiator of blood coagulation and is present in the plasma milieu at very low concentrations, it is an attractive drug target for the design and development of anticoagulants.

So far, only two proteins that specifically inhibit the TF·FVIIa complex have been well characterized, viz. tissue factor pathway inhibitor (TFPI) and nematode anticoagulant peptide c2 (NAPc2). TFPI is an endogenous inhibitor of this complex (40), whereas NAPc2 is an exogenous inhibitor isolated from canine hookworm (Ancylostoma caninum) (41). TFPI is a 42-kDa plasma glycoprotein consisting of three tandem Kunitz-type domains. The first and second units inhibit TF·FVIIa and FXa, respectively. The third Kunitz domain and the C-terminal basic region of the molecule have heparin-binding sites (42). The anticoagulant action of TFPI is a two-stage process. The second Kunitz domain binds first to a molecule of FXa and deactivates it. The first domain then rapidly binds to an adjacent TF·FVIIa complex, preventing further activation of FX (43–45). On the other hand, NAPc2 is an 8-kDa short polypeptide. Its mechanism of action requires prerequisite binding to FXa or zymogen FX to form a binary complex prior to its interaction and inhibition of membrane-bound TF·FVIIa (41). Therefore, despite the structural differences, both inhibitors form a quaternary complex with TF·FVIIa·FXa. However, in both complexes, the active site of FVIIa is occupied by the respective inhibitors and is not accessible.

Because of the lack of natural inhibitors that specifically interfere with FVIIa activity, a number of artificial inhibitors have been designed and developed. They include proteins that block the association of TF and FVIIa, such as antibodies against TF and FVIIa, TFAA (a TF mutant with reduced cofactor function for FX), FFR-VIIa (inactivated form of FVIIa with 5-fold higher affinity for TF compared with native FVIIa), and peptides derived from TF and FVIIa (47–54). In addition, two series of peptide exosite inhibitors were selected from phage display libraries for their ability to bind to the TF·FVIIa complex (47, 48). They bind to two distinct exosites on the serine protease domain of FVIIa and exhibit steric and allosteric inhibition (50). Although both peptide classes are potent and selective inhibitors of the TF·FVIIa complex, they fail to inhibit 100% activity even at saturating concentrations. This is overcome either by the fusion of the two peptides (51) or by using a protease switch with substrate phage (49). A number of synthetic compounds have also been designed as active-site inhibitors of FVIIa as well as the TF·FVIIa complex (52, 55–58). A number of naphthylamidines have recently been reported to have FVIIa inhibitory activity (59). They were synthesized by the coupling of amidinobenzaldehyde analogs to a polystyrene resin. However, apart from inhibiting FVIIa activity, these synthetic compounds nonspecifically inhibit the activity of other blood coagulation serine proteases (59).

Hemextin AB Complex Is a Novel Anticoagulant—We have reported here the isolation and characterization of two proteins, hemextins A and B, from the venom of H. haemachatus that synergistically induce potent anticoagulant activity. Individually, only hemextin A exhibited mild anticoagulant activity, whereas hemextin B had no anticoagulant activity (Fig. 4A). The increase in the anticoagulant potency of hemextin A in the presence of hemextin B (Fig. 4A) indicated probable complex formation between the two proteins. We have shown that 1:1 complex formation is important for potent anticoagulant activity using the prothrombin time assay (Fig. 4B). Complex formation was further confirmed by gel-filtration chromatography (Fig. 5).

Both hemextins A and B belong to the three-finger family of snake venom proteins (Fig. 3A) and not to the family of snake venom serine protease inhibitors. Proteins belonging to this group exhibit a characteristic beta-sheet structure (60), also observed in the CD studies (Fig. 3B). It is a well known fact that disulfide bonds associated with cysteine residues are essential structural units in proteins (61). To evaluate the importance of the three-finger fold in both complex formation and anticoagulant activity, we used reduced and subsequently pyridylethylated hemextins A and B. Upon pyridylethylation, they lost their native three-finger fold, as observed in the CD studies (Fig. 3B). The S-pyridylethylated hemextins were functionally inactive (Fig. 4A, inset) and were unable to bind to each other to form the complex, as evident from the gel-filtration studies (Fig. 5). This shows that proper folding of the proteins is important not only for function, but also for complex formation.

Using the dissection approach (36, 37), we identified the site of anticoagulant action of hemextin A and its synergistic complex. Both hemextin A and the hemextin AB complex inhibited the extrinsic tenase complex, but not other steps in the extrinsic pathway. These results were further confirmed by studying the effect of hemextin A and its complex on the reconstituted TF·FVIIa complex. Both hemextin A and the hemextin AB complex inhibited FXa formation by the reconstituted extrinsic tenase complex (Fig. 6A). Furthermore, hemextin A and the hemextin AB complex inhibited the amidolytic activity of FVIIa in both the presence and absence of sTF (Fig. 7, A and B). The hemextin AB complex inhibited with IC50 values of ~200 and ~210 nM, respectively. Similar IC50 values may be indicative of the fact that hemextin A and the hemextin AB complex do not bind to the cofactor-binding site of FVIIa. The inhibitory activity of hemextin A and the hemextin AB complex may not be due to nonspecific interaction of hemextin A or its complex with the phospholipids in the extrinsic tenase complex, as indicated by their inability to prolong Stypven time, because they failed to inhibit the prothrombinase complex, which is also formed on the phospholipid surfaces. This was further confirmed by determining the inhibitory activity of hemextin A and the hemextin AB complex on the amidolytic activity of the reconstituted extrinsic tenase complex using sTF and FVIIa (Fig. 7B). Furthermore, hemextin A and the hemextin AB complex inhibited the amidolytic activity of FVIIa (Fig. 7A). However, hemextin B did not exhibit any inhibitory activity in the absence of hemextin A. To further characterize the inhibitory properties and to determine the specificity of inhibition, we screened hemextins A and B and the hemextin AB complex against 12 serine proteases. In addition to FVIIa and its complexes, hemextin A and the hemextin AB complex inhibited the amidolytic activity of only kallikrein in a dose-dependent manner (Fig. 8). However, the IC50 for the inhibition of kallikrein was ~10 µM, in contrast to that of FVIIa/TF·FVIIa/sTF·FVIIa, which was ~200 nM. Kinetic studies revealed that the hemextin AB complex is a noncompetitive inhibitor of the sTF·FVIIa complex, with a Ki of 50 nM. Using ITC studies, we have shown that the hemextin AB complex directly interacts with FVIIa (Fig. 10). The binding interaction between FVIIa and the hemextin AB complex is associated with a negative change in free energy, indicating that this complex formation is favored. The negative change in entropy observed upon binding indicates the formation of a tightly folded complex between the two moieties (62). Thus, these data strongly indicate that the hemextin AB complex is a highly specific inhibitor of FVIIa. To our knowledge, this is the first natural inhibitor of FVIIa.

Some other anticoagulants from snake venoms also inhibit the extrinsic tenase complex. However, they are not as specific. For example, CM-IV, a strongly anticoagulant phospholipase A2 from Naja nigricollis venom, prolongs coagulation by inhibiting two successive steps in the coagulation cascade. It inhibits the TF·FVIIa complex by both enzymatic and nonenzymatic mechanisms (63), whereas it inhibits the prothrombinase complex by only a nonenzymatic mechanism (64, 65). Hemextin A and its synergistic complex are the first reported specific inhibitors of FVIIa isolated from snake venom.

The similar dose-dependent inhibition of the TF·FVIIa complex and FVIIa indicates that the hemextin AB complex neither requires TF for its inhibitory activity nor interferes in the binding of TF to FVIIa. Unlike TFPI and NAPc2, it also does not use FXa as a scaffold to bind to FVIIa and thus does not require FX or FXa to inhibit FVIIa. Furthermore, TFPI and NAPc2 bind to the active site of FVIIa. In contrast, as shown by the kinetic studies (Fig. 9), the hemextin AB complex is a noncompetitive inhibitor, unlike competitive inhibitors that bind to the active site. Thus, the hemextin AB complex does not appear to bind to the active site of FVIIa. Therefore, hemextin A and the hemextin AB complex are novel inhibitors of FVIIa and the TF·FVIIa complex.

Hemextin AB Complex Is a Unique Protein Complex—Synergism among snake venom toxins is fairly well characterized, particularly among presynaptic neurotoxins. For example, crotoxin isolated from Crotalus durissus terrificus venom contains two subunits; the basic subunit is a phospholipase A2 enzyme, whereas the acidic subunit is catalytically inactive (although it is derived from a phospholipase A2-like protein) (66). Individually, only the basic subunit is slightly toxic, whereas the complex exhibits potent toxicity. The acidic subunit appears to act as a chaperone and enhances the specific binding of the basic subunit to the presynaptic site. Similarly, other presynaptic neurotoxins, such as taipoxin from Oxyuranus scutellatus (67) and textilotoxin from Pseudonaja textilis (68) venoms, contain three and four subunits, respectively. All the subunits are structurally similar to phospholipase A2 enzymes. The noncovalent interactions between the subunits of these toxins are important for their potent toxicity. Thus, a number of snake venom presynaptic toxins are protein complexes with phospholipase A2 as an integral part. Taicatoxin, another protein complex isolated from O. scutellatus venom, blocks calcium channels and has phospholipase A2, proteinase inhibitor, and neurotoxin (a three-finger toxin) subunits (69). There are only a few noncovalent protein complexes in snake venoms that do not contain phospholipase A2 as an integral part. For example, rhodocetin, an antiplatelet protein complex from Calloselasma rhodostoma venom, contains two subunits showing structural similarity to C-type lectins (70). Group C prothrombin activators from Australian snakes are procoagulant protein complexes that are structurally and functionally similar to mammalian blood coagulation FXa·FVa complexes (46, 71, 72). The hemextin AB complex is a unique snake venom protein complex formed by the interaction between two three-finger toxins, in which the anticoagulant activity of hemextin A is potentiated by its synergistic interaction with hemextin B. It should be noted that crude snake venom does not contain the hemextin AB complex. It is not clear when and how this complex is formed.

In summary, we have described a unique anticoagulant protein complex from snake venom that specifically and noncompetitively inhibits FVIIa activity. Our results strongly indicate that the interaction between hemextins A and B is essential for potent anticoagulant activity. This new anticoagulant may help us develop different strategies and therapeutic agents to inhibit the initiation step in blood coagulation.


   FOOTNOTES
 
* This work was supported in part by the Biomedical Research Council, Agency for Science and Technology, Singapore. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 Recipient of a National University of Singapore research scholarship. Back

2 To whom correspondence should be addressed. Tel.: 65-6874-5235; Fax: 65-6779-2486; E-mail: dbskinim{at}nus.edu.sg.

3 The abbreviations used are: TF, tissue factor; FVIIa, factor VIIa; pNA, p-nitroanilide; 2HCl, dihydrochloride; <Glu, pyroglutamic acid; sTF, soluble tissue factor; HPLC, high pressure liquid chromatography; ITC, isothermal titration calorimetry; TFPI, tissue factor pathway inhibitor; NAPc2, nematode anticoagulant peptide c2. Back


   ACKNOWLEDGMENTS
 
We thank Dr. Prakash Kumar (Department of Biological Sciences, National University of Singapore) for reviewing the manuscript and Dr. Rajamani Lakshminarayanan (Department of Chemistry, National University of Singapore) for helpful discussions. We thank all members of the Factor VII Group of KAKETSUKEN (Kazuhiko Tomokiyo, Yasushi Nakatomi, Teruhisa Nakashima, and Soutatou Gokudan) for providing plasma-derived FVII, FVIIa, FX, and FXa. We also thank Hiroshi Kaetsu, Shinji Nakahira, and Takayoshi Hamamoto for providing plasma-derived thrombin, activated protein C, and FIXa, respectively, and Dr. Toshiyuki Miyata for providing recombinant human sTF. We also thank Kumiko Arita (KAKETSUKEN) for help in kinetic studies.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Davie, E. W., Fujikawa, K., and Kisiel, W. (1991) Biochemistry 30, 10363–10370[CrossRef][Medline] [Order article via Infotrieve]
  2. Davie, E. W. (1995) Thromb. Haemostasis 74, 1–6[Medline] [Order article via Infotrieve]
  3. Mann, K. G., Butenas, S., and Brummel, K. (2003) Arterioscler. Thromb. Vasc. Biol. 23, 17–25[Abstract/Free Full Text]
  4. Rapaport, S. I., and Rao, L. V. (1995) Thromb. Haemostasis 74, 7–17[Medline] [Order article via Infotrieve]
  5. Morrissey, J. H., Macik, B. G., Neuenschwander, P. F., and Comp, P. C. (1993) Blood 81, 734–744[Abstract/Free Full Text]
  6. Nemerson, Y. (1988) Blood 71, 1–8[Free Full Text]
  7. Gustafsson, D., Bylund, R., Antonsson, T., Nilsson, I., Nystrom, J. E., Eriksson, U., Bredberg, U., and Teger-Nilsson, A. C. (2004) Nat. Rev. Drug Discov. 3, 649–659[CrossRef][Medline] [Order article via Infotrieve]
  8. Hirsh, J. (1991) N. Engl. J. Med. 324, 1565–1574[Medline] [Order article via Infotrieve]
  9. Hirsh, J. (1991) N. Engl. J. Med. 324, 1865–1875[Medline] [Order article via Infotrieve]
  10. Hirsh, J., and Weitz, J. I. (1999) Lancet 353, 1431–1436[CrossRef][Medline] [Order article via Infotrieve]
  11. Moll, S., and Roberts, H. R. (2002) Semin. Hematol. 39, 145–157[CrossRef][Medline] [Order article via Infotrieve]
  12. Hirsh, J. (2001) Am. Heart J. 142, S3–S8[CrossRef][Medline] [Order article via Infotrieve]
  13. Morrissey, J. H. (2001) Thromb. Haemostasis 86, 66–74[Medline] [Order article via Infotrieve]
  14. Markland, F. S. (1998) Toxicon 36, 1749–1800[Medline] [Order article via Infotrieve]
  15. Higuchi, S., Murayama, N., Saguchi, K., Ohi, H., Fujita, Y., Camargo, A. C., Ogawa, T., Deshimaru, M., and Ohno, M. (1999) Immunopharmacology 44, 129–135[CrossRef][Medline] [Order article via Infotrieve]
  16. O'Shea, J. C., and Tcheng, J. E. (2002) Expert Opin. Pharmacother. 3, 1199–1210[CrossRef][Medline] [Order article via Infotrieve]
  17. Marcinkiewicz, C. (2005) Curr. Pharm. Des. 11, 815–827[CrossRef][Medline] [Order article via Infotrieve]
  18. Huang, F., and Hong, E. (2004) Curr. Med. Chem. Cardiovasc. Hematol. Agents 2, 187–196[CrossRef][Medline] [Order article via Infotrieve]
  19. Plosker, G. L., and Ibbotson, T. (2003) PharmacoEconomics 21, 885–912[CrossRef][Medline] [Order article via Infotrieve]
  20. Kondo, K., and Umemura, K. (2002) Clin. Pharmacokinet. 41, 187–195[CrossRef][Medline] [Order article via Infotrieve]
  21. McClellan, K. J., and Goa, K. L. (1998) Drugs 56, 1067–1080[CrossRef][Medline] [Order article via Infotrieve]
  22. Sherman, D. G. (2002) Curr. Med. Res. Opin. 18, Suppl. 2, s48–s52
  23. Nakagaki, T., Foster, D. C., Berkner, K. L., and Kisiel, W. (1991) Biochemistry 30, 10819–10824[CrossRef][Medline] [Order article via Infotrieve]
  24. Wildgoose, P., and Kisiel, W. (1989) Blood 73, 1888–1895[Abstract/Free Full Text]
  25. Stone, M. J., Ruf, W., Miles, D. J., Edgington, T. S., and Wright, P. E. (1995) Biochem. J. 310, 605–614
  26. Kaetsu, H., Mizuguchi, J., Hamamoto, T., Kamimura, K., Yoshida, Y., Nakagaki, T., Ogata, Y., Miyamoto, S., and Funatsu, A. (1998) Thromb. Res. 90, 101–109[CrossRef][Medline] [Order article via Infotrieve]
  27. Okajima, K., Koga, S., Kaji, M., Inoue, M., Nakagaki, T., Funatsu, A., Okabe, H., Takatsuki, K., and Aoki, N. (1990) Thromb. Haemostasis 63, 48–53[Medline] [Order article via Infotrieve]
  28. Joseph, J. S., Chung, M. C., Jeyaseelan, K., and Kini, R. M. (1999) Blood 94, 621–631[Abstract/Free Full Text]
  29. Langdell, R. D., Wagner, R. H., and Brinkhous, K. M. (1953) J. Lab. Clin. Med. 41, 637–647[Medline] [Order article via Infotrieve]
  30. Quick, A. J. (1935) J. Biol. Chem. 109, 73–74
  31. Hougie, C. (1956) Proc. Soc. Exp. Biol. Med. 98, 570–573
  32. Jim, R. (1957) J. Lab. Clin. Med. 50, 45–60[Medline] [Order article via Infotrieve]
  33. Condrea, E., Fletcher, J. E., Rapuano, B. E., Yang, C. C., and Rosenberg, P. (1981) Toxicon 19, 61–71[Medline] [Order article via Infotrieve]
  34. Chen, C., Hsu, C. H., Su, N. Y., Lin, Y. C., Chiou, S. H., and Wu, S. H. (2001) J. Biol. Chem. 276, 45079–45087[Abstract/Free Full Text]
  35. Hokama, Y., Iwanaga, S., Tatsuki, T., and Suzuki, T. (1976) J. Biochem. (Tokyo) 79, 559–578[Abstract/Free Full Text]
  36. Kini, R. M., and Banerjee, Y. (2005) J. Thromb. Haemostasis 3, 170–171[CrossRef]
  37. Stefansson, S., Kini, R. M., and Evans, H. J. (1989) Thromb. Res. 55, 481–491[CrossRef][Medline] [Order article via Infotrieve]
  38. Maun, H. R., Eigenbrot, C., Raab, H., Arnott, D., Phu, L., Bullens, S., and Lazarus, R. A. (2005) Protein Sci. 14, 1171–1180[Abstract/Free<